1 Min Read
June 26 (Reuters) - Matinas Biopharma Holdings Inc:
* Matinas Biopharma reports topline data from phase 2 clinical study of orally-administered mat2203 for the treatment of vulvovaginal candidiasis Source text for Eikon: Further company coverage:
All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.
© 2017 Reuters. All Rights Reserved.